FK 506 in clinical kidney transplantation.
Ron Shapiro(University of Pittsburgh), Mark L. Jordan(University of Pittsburgh), Velma P. Scantlebury(University of Pittsburgh), John J. Fung(University of Pittsburgh), Christopher Jensen(University of Pittsburgh), Andreas G. Tzakis(University of Pittsburgh), J McCauley(University of Pittsburgh), P. B. Carroll(University of Pittsburgh), Camillo Ricordi(University of Pittsburgh), Anthony J. Demetris(University of Pittsburgh)
PubMed
December 1, 1991
Cited by 112Open Access
Abstract
Early reports on the use of FK 506 after kidney transplantation emphasized the ability to stop prednisone in a significant percentage of successfully transplanted patients.1,2 In addition, there was a relative freedom from antihypertensive agents and a tendency toward low serum cholesterol levels. This report will summarize our experience to date with FK 506 in renal transplantation and will compare the results with a nearly concurrent group of patients treated with cyclosporine (CyA)-based immunosuppression.